Currently Viewing:
Evidence-Based Oncology The American Society of Clinical Oncology Annual Meeting, 2015

New Oncology Clinical Trial Designs: What Works and What Doesn't?

Surabhi Dangi-Garimella, PhD
Basket and umbrella studies as well as adaptive enrichment design strategies represent novel approaches to testing targeted therapeutics in oncology, and a session at ASCO's annual meeting discussed the nuts and bolts of these design strategies.

Several criteria influence the drug selection process, she said. The molecules could be FDA-approved for a predictive indication, or have a biomarker; investigational drugs can be included if they have predictive molecular value.

Dahlberg concluded: “Basket design can accelerate the delivery of the right treatment to a patient, but it requires that strong biomarkers be associated with the drug. Additionally, heterogeneity in response across disease types is a primary consideration, and clonal variation has to be adapted during trial design.”


1. NCI-Molecular Analysis for Therapy Choice Program (NCI-MATCH). National Cancer Institute website. Accessed June 12, 2015.
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up